Competition intensifies in already crowded multiple sclerosis space
05/09/19 -"Novartis’ Arzerra is all set to enter the fast-growing/crowded MS space (likely in 2020) banking on superior clinical data vs. Sanofi’s Aubagio. While this would dent the sales of Aubagio, Novartis’ ..."
Pages
66
Language
English
Published on
05/09/19
You may also be interested by these reports :
25/11/25
CureVac’s Q3 sales surpassed market expectations, driven by a one-off contribution from GSK. The operating profit benefited from the resolution of ...
25/11/25
Even though the sentiment around Novo has been extremely adverse (further exacerbated by today’s R&D development around Alzheimer’s), in our opinion, ...
21/11/25
Ever since Sandoz demerged from Novartis, the generics/biosimilars giant has been delivering on its promises, and remains well on track to achieve ...
19/11/25
AstraZeneca has been beating the street’s estimates over the last few quarters, on the back of strong growth momentum for its oncology, rare disease, ...